EP2097410A4 - HETEROYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS - Google Patents

HETEROYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS

Info

Publication number
EP2097410A4
EP2097410A4 EP07833072A EP07833072A EP2097410A4 EP 2097410 A4 EP2097410 A4 EP 2097410A4 EP 07833072 A EP07833072 A EP 07833072A EP 07833072 A EP07833072 A EP 07833072A EP 2097410 A4 EP2097410 A4 EP 2097410A4
Authority
EP
European Patent Office
Prior art keywords
heteroyl
cannabinoid
receptor antagonists
pyrazole derivatives
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07833072A
Other languages
German (de)
French (fr)
Other versions
EP2097410A1 (en
Inventor
Jinhwa Lee
Jeong Min Kim
Chong-Hwan Jonathan Chang
Suk Ho Lee
Hee Jeong Seo
Suk Youn Kang
Kwang-Seop Song
Jong Yup Kim
Min Ju Kim
Sung-Han Lee
Kwang-Woo Ahn
Myung Eun Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GC Biopharma Corp
Original Assignee
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/541,269 external-priority patent/US20080081815A1/en
Application filed by Green Cross Corp Korea filed Critical Green Cross Corp Korea
Publication of EP2097410A1 publication Critical patent/EP2097410A1/en
Publication of EP2097410A4 publication Critical patent/EP2097410A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EP07833072A 2006-09-29 2007-09-28 HETEROYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS Withdrawn EP2097410A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/541,269 US20080081815A1 (en) 2006-09-29 2006-09-29 Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
KR20060132606 2006-12-22
PCT/KR2007/004754 WO2008039023A1 (en) 2006-09-29 2007-09-28 Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists

Publications (2)

Publication Number Publication Date
EP2097410A1 EP2097410A1 (en) 2009-09-09
EP2097410A4 true EP2097410A4 (en) 2009-11-25

Family

ID=39234790

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07833072A Withdrawn EP2097410A4 (en) 2006-09-29 2007-09-28 HETEROYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS

Country Status (5)

Country Link
EP (1) EP2097410A4 (en)
JP (1) JP5269795B2 (en)
KR (1) KR101100028B1 (en)
CN (1) CN101528740B (en)
WO (1) WO2008039023A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
DK2280961T3 (en) * 2008-04-22 2012-08-27 Lilly Co Eli 1,5-DIPHENYL-PYRROLIDIN-2-ON COMPOUNDS AS CB-1 LIGANDS
JP5539322B2 (en) * 2008-04-22 2014-07-02 イーライ リリー アンド カンパニー 1,5-Diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
PL2703392T3 (en) * 2011-04-27 2017-11-30 Shionogi & Co., Ltd. 5-membered ring aromatic heterocyclic derivative having npy y5 receptor antagonistic activity
WO2013005168A2 (en) * 2011-07-05 2013-01-10 Lupin Limited Cannabinoid receptor modulators
TWI673429B (en) 2013-03-14 2019-10-01 美商漢特道格拉斯股份有限公司 Methods and apparatus to control an architectural opening covering assembly
WO2015162452A1 (en) * 2014-04-23 2015-10-29 Piramal Enterprises Limited Substituted pyrazole compounds as cb1 receptor antagonists and uses thereof
CN108586436A (en) * 2018-07-06 2018-09-28 南京大学 Bishydrazide derivative of one kind skeleton containing indoles and its preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100826A2 (en) * 2001-06-08 2002-12-19 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
WO2005018645A1 (en) * 2003-08-21 2005-03-03 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of addiction in a mammal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
DE2906252A1 (en) * 1979-02-19 1980-08-28 Merck Patent Gmbh PYRAZOLE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND METHOD FOR THE PRODUCTION THEREOF
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2714057B1 (en) 1993-12-17 1996-03-08 Sanofi Elf New derivatives of 3-pyrazolecarboxamide, process for their preparation and pharmaceutical compositions containing them.
DE60130891T2 (en) * 2000-06-29 2008-07-17 Anthera Pharmaceuticals Inc., San Mateo REMEDIES FOR CANCER
ATE548037T1 (en) 2002-12-18 2012-03-15 Glaxosmithkline Llc PEPTIDE DEFORMYLASE INHIBITORS
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
AU2005230864A1 (en) * 2004-03-29 2005-10-20 Merck Sharp & Dohme Corp. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
FR2882365B1 (en) * 2005-02-21 2007-09-07 Sanofi Aventis Sa 2- (1,5-DIPHENYL-1H-PYRAZOL-3-YL) -1,3,4-OXADIAZOLE DERIVATIVES AND THEIR PREPARATION AND THERAPEUTIC USE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100826A2 (en) * 2001-06-08 2002-12-19 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
WO2005018645A1 (en) * 2003-08-21 2005-03-03 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of addiction in a mammal

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE , (3), 917-24 CODEN: BSCFAS; ISSN: 0037-8968, 1971 *
CHEMISCHE BERICHTE , 90, 2401-4 CODEN: CHBEAM; ISSN: 0009-2940, 1957 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ARRIETA, ANA ET AL: "Efficient tautomerization hydrazone-azomethine imine under microwave irradiation. Synthesis of [4,3'] and [5,3']bipyrazoles", XP002550426, retrieved from STN Database accession no. 1998:678997 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BERGEON, MARIE T. ET AL: "Sulfurated organic compounds. VIII. Reaction of phenylhydrazine with 3-aryl-1,2-dithiolylium bisulfates and 3,5-diaryl-1,2-dithiolylium perchlorates. 3-Aryl-1-phenylpyrazoles, 5-aryl-1-phenylpyrazoles, and 3,5-diaryl-1-phenylpyrazoles", XP002550424, retrieved from STN Database accession no. 1971:420283 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CARRILLO, J. R. ET AL: "A complete model for the prediction of 1H- and 13C-NMR chemical shifts and torsional angles in phenyl-substituted pyrazoles", XP002550430, retrieved from STN Database accession no. 2001:321317 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FINAR, I. L. ET AL: "Preparation of some pyrazole derivatives", XP002550431, retrieved from STN Database accession no. 1959:94763 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FINAR, I. L.: "Preparation and properties of some bipyrazolyls", XP002550425, retrieved from STN Database accession no. 1956:12288 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MASLIVETS, A. N. ET AL: "Five-membered 2,3-dioxo heterocycles. XI. Synthesis and chemical transformations of .beta.-aroylhydrazides of aroylpyruvic acids", XP002550421, retrieved from STN Database accession no. 1990:55776 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MILLER, SIDNEY I. ET AL: "Mass spectra of 1,2,3-triazoles", XP002550429, retrieved from STN Database accession no. 1979:473771 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PFLEGER, ROBERT ET AL: ".alpha.-Acylaminoacrylic acid. VII. The action of hypobromite on .alpha.-acetamidocinnamic acid", XP002550428, retrieved from STN Database accession no. 1958:113664 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SHIMANSKAYA, N. P. ET AL: "Polarographic study of derivatives of .DELTA.2-pyrazoline", XP002550422, retrieved from STN Database accession no. 1968:512873 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SHIRONINA, T. M. ET AL: "1,3,4,6-Tetracarbonyl compounds: IV. Reaction of 3,4-dihydroxy-2,4-hexadiene-1,6-diones with hydrazine and arylhydrazines", XP002550427, retrieved from STN Database accession no. 2002:136610 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SHKUMAT, A. P.: "Search for new luminophores with predetermined physicochemical and chemical properties. I. 1,3,5-Triarylpyrazoles", XP002550423, retrieved from STN Database accession no. 2000:55923 *
JOURNAL OF THE CHEMICAL SOCIETY 1205-8 CODEN: JCSOA9; ISSN: 0368-1769, 1955 *
JOURNAL OF THE CHEMICAL SOCIETY 1819-23 CODEN: JCSOA9; ISSN: 0368-1769, 1959 *
JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY (1972-1999) , (1), 15-19 CODEN: JCPRB4; ISSN: 0300-922X, 1979 *
RUSSIAN JOURNAL OF ORGANIC CHEMISTRY (TRANSLATION OF ZHURNAL ORGANICHESKOI KHIMII) , 37(10), 1486-1494 CODEN: RJOCEQ; ISSN: 1070-4280, 2001 *
See also references of WO2008039023A1 *
TETRAHEDRON , 54(43), 13167-13180 CODEN: TETRAB; ISSN: 0040-4020, 1998 *
TETRAHEDRON , 57(19), 4179-4187 CODEN: TETRAB; ISSN: 0040-4020, 2001 *
VISNIK KHARKIVS'KOGO UNIVERSITETU , (2(CHEM.)), 121-125 CODEN: VKSGA3; ISSN: 0453-8048, 1998 *
ZHURNAL OBSHCHEI KHIMII , 38(8), 1676-9 CODEN: ZOKHA4; ISSN: 0044-460X, 1968 *
ZHURNAL ORGANICHESKOI KHIMII , 25(5), 1039-45 CODEN: ZORKAE; ISSN: 0514-7492, 1989 *

Also Published As

Publication number Publication date
EP2097410A1 (en) 2009-09-09
CN101528740B (en) 2012-09-19
CN101528740A (en) 2009-09-09
JP2010504961A (en) 2010-02-18
KR20090061076A (en) 2009-06-15
WO2008039023A1 (en) 2008-04-03
KR101100028B1 (en) 2011-12-29
JP5269795B2 (en) 2013-08-21

Similar Documents

Publication Publication Date Title
EP2013169A4 (en) INDOLAMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
EP2097410A4 (en) HETEROYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS
EP2342201A4 (en) INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS
EP2035376A4 (en) INDOLINE AMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS
EP2032570A4 (en) AZACYCLOPENTANE DERIVATIVES AS DELTA-9 DEATURASE STEAROYL COENZYME INHIBITORS
EP1966183A4 (en) HETEROAROMATIC COMPOUNDS AS DELTA-9 DEATURASE STÉAROYL-COENZYME INHIBITORS
EP2049110A4 (en) DIAZEPANS ANTAGONIST OF THE ORTEXIN RECEPTOR
EP2066689A4 (en) HYD1 PEPTIDES AS ANTICANCER AGENTS
DE602007006531D1 (en) PYRAZIN-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS
EP2103619A4 (en) IMIDAZOTHIAZOLE DERIVATIVES
ATE413874T1 (en) NEW THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR ANTAGONISTS
ATE509928T1 (en) 8-AZABICYCLOÄ3.2.1ÜOCTANE COMPOUNDS AS MU-OPIOID RECEPTOR ANTAGONISTS
EP2378877A4 (en) IMIDAZOLINONE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS
ATE505467T1 (en) 2-AZA-BICYCLOÄ3.1.0UHEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
ATE536355T1 (en) 3,3-SPIROINDOLINION DERIVATIVES AS ANTICANCER AGENTS
EP2038758A4 (en) INTEGRATED APPLICATION GATEWAY
EP2010526A4 (en) Benzimidazole 5-sulfonamide derivatives as cannabinoid 1 (cb1) receptor ligands
ATE523195T1 (en) NEW THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR ANTAGONISTS
EP1915372A4 (en) INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS
EP2138484A4 (en) FUSIONED BICYCLIC HETERRO-ARYL DERIVATIVES
EP2306436A4 (en) ARTICULATED KNEE FOR SIMULATION OF ARTHROSCOPY
EP2170064A4 (en) ANTAGONISTS 6,5-PYRROLOPIPERIDINE OF TACHYKININ RECEPTORS
DE602006004997D1 (en) INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE V1A RECEPTOR
ATE495167T1 (en) PIPERIDINE-4-YL-PYRIDAZINE-3-YL AMINE DERIVATIVES AS RAPID DISSOCIATION ANTAGONISTS OF THE DOPAMINE 2 RECEPTOR
IL194902A0 (en) Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090330

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/04 20060101ALI20091015BHEP

Ipc: A61K 31/4155 20060101ALI20091015BHEP

Ipc: A61K 31/415 20060101ALI20091015BHEP

Ipc: A61P 29/00 20060101ALI20091015BHEP

Ipc: C07D 413/04 20060101ALI20091015BHEP

Ipc: C07D 419/04 20060101AFI20080428BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20091023

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100720

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 401/14 20060101ALI20140909BHEP

Ipc: C07D 413/14 20060101ALI20140909BHEP

Ipc: C07D 403/04 20060101ALI20140909BHEP

Ipc: C07D 419/04 20060101AFI20140909BHEP

Ipc: A61K 31/4155 20060101ALI20140909BHEP

Ipc: A61K 31/415 20060101ALI20140909BHEP

Ipc: C07D 417/14 20060101ALI20140909BHEP

Ipc: C07D 403/14 20060101ALI20140909BHEP

Ipc: A61P 29/00 20060101ALI20140909BHEP

Ipc: C07D 409/14 20060101ALI20140909BHEP

Ipc: C07D 417/04 20060101ALI20140909BHEP

Ipc: C07D 405/14 20060101ALI20140909BHEP

Ipc: A61P 3/04 20060101ALI20140909BHEP

Ipc: C07D 413/04 20060101ALI20140909BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20141021

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150303